-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Zhong Guisheng Research Group of ShanghaiTech University and the Wang Haopeng Research Group cooperated to publish research papers
The COVID-19 pandemic has severely impacted human health and socio-economic life
In this work, the joint team first designed a series of candidate vaccines based on different domains of the new coronavirus spike protein, and used mouse model systems to investigate the immunogenicity of different domains, and found that the S1 antigen was able to induce the highest level of spike-specific IgG antibody, and the ratio of IgG2a to IgG1 induced was close to 1, indicating that the antigen activated a more balanced Th1/Th2 immune response
Figure 1.
The research team further investigated the ability of AAV-ie-S1 to
The results of the neutralization and viability of vaccine immune serum on different new coronavirus variants showed that AAV-ie-S1 can effectively neutralize new coronavirus variants, including omicron variants
Figure 2.
Although live virus neutralization activity and in vivo experiments in animals are still ongoing, this study has suggested the feasibility of AAV vector as a vaccine delivery vector, and verified the characteristics of AAV vector vaccine as efficient, safe, stable and single-dose vaccination
The paper is titled "A protective AAV vaccine for SARS-CoV-2
Paper Link:
